About RIT, van Rij et al (41) previously reported that TROP2-expressing prostate cancer can be targeted efficiently with TF12 [anti-TROP2 × anti-HSG (histamine-succinyl-glycine)] and 177Lu-labeled diHSG-peptide (IMP288). This evidence concerns the gene TACSTD2 and prostate carcinoma.